JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares. Alyftrek’s approval with a higher U.S. price than Trikafta sets the stage for continued Cystic Fibrosis revenue growth in 2025, says the analyst following the “ahead-of-schedule but widely-expected approval.” The firm sees an attractive buying opportunity created by suzetrigine’s “underwhelming” Phase 2 results and views the stock as “likely to work higher in 2025 with two key launches and multiple potential pipeline updates,” the analyst tells investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug
- Vertex announces FDA approval of Alyftrek
- Vertex announces FDA exands approval for Trikafta
- Channel Therapeutics highlights difference between NaV1.7, NaV1.8
- Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
